<DOC>
	<DOCNO>NCT01255046</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety STA-1 v placebo add-on treatment donepezil patient mild moderate Alzheimer 's Disease ( AD ) .</brief_summary>
	<brief_title>Study STA-1 Add-on Treatment Donepezil</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Male female patient age â‰¥ 50 year ; Probable Alzheimer 's disease diagnose National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criterion ; MMSE score 1026 , inclusive ; Patient treat donepezil 10 mg per day least 3 month prior screen ; Patient able participate study evaluation ingest oral medication indicate ; Patient responsible caregiver accompany patient clinic visit study ; Patient responsible caregiver provide write informed consent undergo study procedure . Brain image ( compute tomography ( CT ) scan Magnetic Resonance Imaging ( MRI ) do within past 12 month prior study ) laboratory test exclude secondary dementia nonAlzheimer 's dementia ; Patient significant clinically central nervous system illness AD ( e.g . Parkinson 's disease , Human Immunodeficiency Virus ( HIV ) induce dementia , Hachinski Ischaemic Score ( HIS ) &gt; 4 ) dementia complicate organic disease delirium ; Patient severe uncontrolled Diagnostic Statistical Manual Mental Disorders ( DSMIV ) Axis I disorder Alzheimer 's disease , include amnestic disorder , schizophrenia schizoaffective disorder , bipolar disorder , current major depressive episode , psychosis , panic , posttraumatic stress disorder ; Patient suffer cerebral disturbance follow stroke cerebral trauma ( event occur within last 6 month ) ; Patient history hypersensitivity study drug ; Patient history evidence medical condition would expose undue risk significant adverse event interfere assessment safety efficacy course trial , include limited hepatic , renal , respiratory , cardiovascular , endocrine ( e.g. , Addison 's Disease ) , immune , neurologic , hematologic disease determine clinical judgment investigator ; Participation research study within last 30 day ; Patient significant alcohol drug abuse judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>